Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of small-molecule therapies for oncology and immunology-related indications. The company operates within the biotechnology and pharmaceutical research industry, with an emphasis on identifying and advancing drug candidates that address unmet medical needs. XTL does not currently market approved products and does not generate recurring commercial revenue, relying instead on research and development activities and external financing.
Historically, XTL was founded in 1993 and originally focused on treatments for hepatitis B and hepatitis C. Over time, following clinical trial outcomes and strategic reassessments, the company shifted its focus toward oncology and immune-mediated diseases. Its evolution reflects a transition from antiviral research to a broader biopharmaceutical R&D model centered on targeted therapeutic mechanisms.
Business Operations
XTL Biopharmaceuticals operates primarily through internal research and development activities, with its business model centered on the discovery, preclinical development, and clinical evaluation of drug candidates. The company’s operations are organized around advancing a limited number of pipeline assets rather than diversified commercial segments. As of publicly available disclosures, its lead programs are in oncology-related indications, including solid tumors, utilizing proprietary or in-licensed compounds.
The company conducts much of its scientific and clinical work through outsourced arrangements, including contract research organizations for preclinical studies and clinical trials. XTL does not maintain manufacturing operations and has no reported revenue-generating subsidiaries. Its operational footprint is relatively lean, reflecting its status as a development-stage biotechnology company.
Strategic Position & Investments
XTL’s strategic direction is focused on value creation through clinical advancement and potential partnering or licensing opportunities rather than near-term commercialization. Growth initiatives are centered on advancing existing pipeline assets through defined clinical milestones to enhance their strategic value. The company has historically explored collaborations and licensing arrangements to supplement internal capabilities and manage development risk.
The company does not report a broad portfolio of operating subsidiaries or controlling interests in other businesses. Investment activity has primarily been directed toward internal R&D expenditures rather than acquisitions. Public disclosures indicate that XTL continuously evaluates new therapeutic opportunities aligned with its oncology and immunology focus, though specific emerging technologies or future programs are subject to development and regulatory outcomes.
Geographic Footprint
XTL Biopharmaceuticals is headquartered in Israel, with its principal executive offices located in Rehovot, Israel. The company’s core management and strategic decision-making functions are based there. Research activities are conducted both domestically and through international service providers, particularly in North America and Europe, where clinical trials and regulatory interactions commonly take place.
While XTL does not maintain a broad physical presence across multiple continents, its operational reach is international in nature due to its reliance on global clinical trial sites, regulatory agencies, and scientific collaborators. Its ordinary shares are publicly traded in the United States, providing access to international capital markets.
Leadership & Governance
XTL Biopharmaceuticals is led by an experienced management team with backgrounds in biotechnology, pharmaceuticals, and corporate finance. The company emphasizes a governance approach focused on capital discipline, scientific rigor, and strategic flexibility, reflecting its development-stage status.
Key executives include:
- Nick Pope – Chief Executive Officer
- Kobi Richter – Chairman of the Board
- Yael Weiss – Chief Financial Officer
- Dr. Iris Lavon – Vice President, Research and Development
The leadership team oversees corporate strategy, pipeline development, and investor relations, with the board providing oversight on long-term direction, risk management, and regulatory compliance.